Plus LibraryBy pinki@katapult.biz / February 13, 2025 Speciality — Amyotrophic Lateral Sclerosis (ALS) Biomarkers Biosimilars Bladder Blood Bone Brain Breast Cancer Central Nervous System (CNS) Clinical Trials Colon Colorectal Diversity, Equity & Inclusion Featured Content Gastrointestinal Genitourinary Genomic Geriatric Gynecology Head and Neck Hematologic Hematologic Maglinencies Hematology Immunotherapy Interventional Radiology Kidney Leukemia Liquid Biopsy Liver Lung Lymphoma Malignencies Melanoma Myelodysplastic Syndrome Myeloma Neuroendocrine Novel Oral & Maxillofacial Surgery Ovarian Pancreas Pancreatic Pharmacological Prostate Radiation Radiology Renal Sarcoma Skin Solid Tumor Supportive & Palliative Care Survivorship Telemedicine Thoracic Thrombosis Thymic Thyroid Urothelial Author / Speaker Title of Presentation Type of Media — Video Document Audio Event 2024 Event — 2024 California Cancer Consortium Conference (CCC) 2024 MLS Cleveland 2024 MLS Nashville 2024 MLS New Orleans 2024 MLS Seattle 2024 New Orleans Summer Cancer Meeting (NOSCM) 2024 PRIMO 2024 SPS Puerto Rico 2024 SPS Seattle 2024 SPECTRUM 2024 Sylvester APP Oncology Symposium 2024 WCS 2024 MaTOS Lungs 2025 PRIMO Clear Displaying 1,701 - 1,725 of 2,875 « 1 … 67 68 69 70 71 … 115 » Surgery for Early-Stage NSCLC Johannes Kratz, MD, PhD View Video Stage III NSCLC– Surgical/ Combined Modality Johannes R. Kratz, MD View PDF Stage III NSCLC– Surgical/ Combined Modality Johannes R. Kratz, MD View Video Surgery for Early-Stage NSCLC Johannes R. Kratz, MD View PDF Stage III NSCLC – Surgical/Combined Modality Johannes R. Kratz, MD View PDF Surgery for Early-Stage NSCLC Johannes R. Kratz, MD View Video Stage III NSCLC – Surgical/Combined Modality Johannes R. Kratz, MD View Video Exon 20 and Uncommon EGFR Sensitive Mutations John Heymach, MD View PDF RET and NTRK: The Good, The Bad, The Ugly.... and What’s Coming Up? John Heymach, MD View PDF Exon 20 and Uncommon EGFR Sensitive Mutations John Heymach, MD View Video RET and NTRK: The Good, The Bad, The Ugly.... and What’s Coming Up? John Heymach, MD View Video Novel Mechanisms of Resistance Identified for Diverse TKIs in NSCLC John Heymach, MD, PhD View PDF Novel Mechanisms of Resistance Identified for Diverse TKIs in NSCLC John Heymach, MD, PhD View Video Updates in Targeted Therapy for NSCLC Jonathan Riess - MD - MS View Video New Therapeutic Directions in Lung Cancer Jonathan Riess, MD View PDF Management of EGFR-mutant NSCLC Jonathan Riess, MD, MS View PDF Targeted Therapy for NSCLC Jonathan Riess, MD, MS View PDF Lung Cancer Case Jonathan Riess, MD, MS View PDF Updates in Targeted Therapies for NSCLC Jonathan Riess, MD, MS View PDF Lung Cancer Case Jonathan Riess, MD, MS View Video Targeted Therapy for NSCLC Jonathan Riess, MD, MS View Video ALK, ROS1 & BRAF Mutations in NSCLC Jonathan Riess, MD, MS View Video ALK, ROS1 & BRAF Mutations in NSCLC Jonathan Riess, MD, MS View PDF Lung Cancer With EGFR Exon 19 and L858R Mutations: The Optimal Front Line Therapy Jonathan Riess, MD, MS View PDF Lung Cancer With EGFR Exon 19 and L858R Mutations: The Optimal Front Line Therapy Jonathan Riess, MD, MS View Video
